CD8A and neoplasm: developed a living bacterial vaccine platform based on a genetically engineered derivative of the probiotic E. coli Nissle 1917.[32] This strain was designed to express tandem neoantigen peptides derived from tumor‐specific mutated epitopes, capable of simultaneously activating both CD8+ CTLs and CD4+ helper T cells (Figure 3b).